We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb<sup>®</sup> immunoadsorption.
- Authors
Rabitsch, W; Knöbl, P; Prinz, E; Keil, F; Greinix, H; Kalhs, P; Worel, N; Jansen, M; Hörl, W H; Derfler, K
- Abstract
Summary:Delayed donor red cell engraftment and prolonged red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible myeloablative and nonmyelo-ablative hematopoietic stem cell transplantation (HSCT). There is an intense debate about the impact on outcome, severity of hemolysis, association with graft-versus-host disease and survival after blood group-incompatible stem cell transplantation. Therefore, therapeutic strategies should be considered to avoid these possible complications. We present five patients, who received allogeneic HSCT from human leukocyte antigen-identical donors for hematological malignancies, which were treated with Ig-Therasorb® immunoadsorption (five treatments/week) to remove persisting incompatible isohemagglutinins. After a median of 17 treatments (range 9-25), all the patients became transfusion independent with the presentation of donor's blood group. No side effects occurred during treatment. Ig-Therasorb® immunoadsorption seems to be a promising therapeutic method for rapid, efficient and safe elimination for persisting isohemagglutinins for patients with PRCA after allogeneic hematological stem cell transplantation.Bone Marrow Transplantation (2003) 32, 1015-1019. doi:10.1038/sj.bmt.1704264
- Subjects
PURE red cell aplasia; ERYTHROCYTES; STEM cell transplantation; BLOOD agglutination; IMMUNOADSORPTION
- Publication
Bone Marrow Transplantation, 2003, Vol 32, Issue 10, p1015
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1704264